Marwan Fakih, MD
Several key findings in metastatic colorectal cancer (mCRC) presented at the 2019 Gastrointestinal Cancers Symposium underscored the importance of understanding tumor biology, explained Marwan Fakih, MD.
State of the Science Summit™ on Gastrointestinal Malignancies, Fakih, who is also co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discussed these trials and highlighted other ongoing research in the field.
OncLive: What were some of the biggest updates from the 2019 Gastrointestinal Cancers Symposium?
: There are 2 main presentations that are important in the research and clinical practice setting of colon cancer. The first study looked at the role of immunotherapy in patients who had progressed on systemic chemotherapy. In this particular phase II trial, patients were randomized to receive a combination of durvalumab and tremelimumab [plus best supportive care] or best supportive care alone. Although we did not see any major responses or significant improvement in PFS in the immunotherapy arm, there was a significant trend in improvement in OS in patients who received the combination. Granted, the improvement was not that clinically significant.
... to read the full story